Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call Transcript
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call Transcript November 18, 2024Cellectar Biosciences, Inc. misses on earnings expectations.
Cellectar Biosciences Inc. (CLRB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 3,197,394 | $6,842,424 | +6% | 1.92% |
| 2. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,712,443 | $5,804,629 | +48% | 0.29% |
| 3. | ADAR1 Capital Management Daniel Schneeberger | 1,022,161 | $2,187,425 | +50% | 0.35% |
| 4. | Altium Capital Jacob Gottlieb | 215,000 | $460,100 | 0.13% | |
| 5. | 33,800 | $72,332 | +18% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.04 | 25,000 | Director | 25,000 | 2021-09-14 | Filing | |
| $1.04 | 19,417 | Director | 19,417 | 2021-09-03 | Filing | |
| $1.70 | 5,100 | Officer, Director | 86,401 | 2021-03-04 | Filing | |
| $1.35 | 37,037 | Officer, Director | 81,301 | 2020-12-28 | Filing | |
| $1.35 | 29,630 | Officer | 102,148 | 2020-12-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.21 | 53 | Director | 0 | 2018-11-29 | Filing | |
| $2.21 | 939 | Director | 53 | 2018-11-29 | Filing | |
| $1.18 | 13,000 | Officer | 67,000 | 2018-03-13 | Filing | |
| $1.20 | 34,000 | Officer, Director | 213,548 | 2018-03-12 | Filing | |
| $1.49 | 5,214 | Director | 626,103 | 2017-11-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,005,658 | $5,555,673 | 4.57% | |
| 2. | 693,909 | $1,922,128 | 1.03% | |
| 3. | 482,890 | $1,337,605 | 0% | |
| 4. | 68,870 | $190,829 | 0% | |
| 5. | 57,042 | $158,006 | 0% |
News See All
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Cellectar Biosciences Second Quarter 2024 Financial Results Call. Today’s call is being recorded.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Call Transcript
Operator: Good morning and welcome to Cellectar Biosciences First Quarter 2024 Earnings Call. Today's call is being recorded.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript
Operator: Good morning. And welcome to Cellectar Biosciences 2023 Yearend Earnings Call. Today's call is being recorded.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today's conference is being recorded.
10 Best Biotech Penny Stocks To Buy Now
Like all sectors of the economy right now, the biotech sector is going through a lot of pain.
Is Cellectar Biosciences (CLRB) A Good Stock To Buy According To Hedge Funds?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.
Here's How Hedge Funds Traded Cellectar Biosciences, Inc. (CLRB) During The Crash
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Cellectar Biosciences (CLRB), Juno Therapeutics (JUNO), Newmont Mining (NEM) and More: What is Going on With These Falling Stocks?
At a time when the broader indexes are rather quiet, Cellectar Biosciences Inc (NASDAQ:CLRB), Juno Therapeutics Inc (NASDAQ:JUNO), Newmont Mining Corp (NYSE:NEM), Barrick Gold Corporation (USA) (NYSE...
Movers In Biotech: Cellectar Biosciences Inc (CLRB) And The Medicines Company (MDCO)
We’ve had another big day in biotech, and a number of companies have moved on news and fundamental developments.
Billionaire Hedge Funds
